Press Release

The latest news from and about Adial and important reporting about the field of addiction.

View All News

Adial Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell this Morning at 9:30 AM Eastern

CHARLOTTESVILLE, Va., Sept. 04, 2018 — Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction and its lead drug for alcohol use disorder (AUD), will ring The Nasdaq Stock Market Opening Bell at the Nasdaq MarketSite in Times Square at 9:30 AM Eastern time today, Tuesday, September 4, 2018. The bell ringing ceremony will be held in honor of Adial Pharmaceuticals’ recent initial public offering (IPO) and listing on the Nasdaq Stock Market.

“We are honored to ring the opening bell this morning in celebration of our IPO and listing on Nasdaq,” said William Stilley, Chief Executive Officer of Adial Pharmaceuticals. “Alcohol Use Disorder is a devastating disease, which takes an enormous toll on our families, our communities, our country and the economy. As recently reported in The Lancet, alcohol is the number one cause of death among both men and women ages 15 to 49 years. And while the war on opioids has been prominently featured in the news, alcoholism has been widely underreported, due in part to the fact that there are very limited options available for patients. We look forward to advancing our lead investigational new drug product, AD04, a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder, and potentially other addictions. I’d like to thank our employees, investors and partners who assisted with our IPO, and we look forward to driving value for shareholders, while providing new hope for patients suffering from this terrible disease.”

A live webcast of The Nasdaq Stock Market Opening Bell ceremony will be available at:

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (“AUD”) using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.

Forward Looking Statements

This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements are based upon current beliefs, expectations and assumptions and include statements regarding advancing AD04 for the treatment of Alcohol Use Disorder, and potentially other addictions, and driving value for our shareholders. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, advancing our lead investigational new drug product, the ability of AD04 therapy to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, our ability to become a leading player in the war on addiction, our ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate, our ability to establish and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, and our ability to retain our key employees and maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our registration statement on Form S-1 that we have filed with the SEC and the final prospectus. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.


Crescendo Communications, LLC
David Waldman/Natalya Rudman
Tel: 212-671-1021


Shep Doniger
Black Dog Communications Group
Tel: 561-637-5750